Affibody’s ABY-271 breast cancer trial cleared to progress to next phase
Affibody has received a recommendation from its Trial Review Committee (TRC) to proceed to the second part of its Phase …
Post
-
-
Precision medicine approaches needed in oncology to match evolving SoC
As the standard of care (SoC) for new drugs in oncology continues to improve, trials need to be designed with …
-
Clinical Trials Arena Excellence Awards 2025: Kairos Pharma
Photo Credit: NYSE Kairos Pharma, a clinical-stage biopharmaceutical company spun out of Cedars-Sinai Medical Center, is focused on overcoming cancer drug …
-
First patient treated in trial of Beacon Therapeutics’ XLRP treatment
Beacon Therapeutics has treated the first patient in its open-label LANDSCAPE trial of the potential gene therapy, laru-zova (laruparetigene zovaparvovec), …
-
Clinical Trials Arena Excellence Awards 2025: Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical‑stage biopharmaceutical company focused on oncology and other areas of high unmet clinical need, has won …
-
Clinical Trials Arena Excellence Awards 2025: BostonGene
BostonGene has received both Research & Development and Innovation awards in the 2025 Clinical Trials Arena Excellence Awards, recognizing its …
-
Aviceda Therapeutics to advance eye disease drug despite Phase IIb loss
Aviceda Therapeutics’ eye disease drug will advance to Phase III, despite it failing to meet the primary endpoint in a …
-
Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win
Immunome is seeking US approval for its gamma secretase inhibitor (GSI) for the treatment of desmoid tumours after the drug …
-
Why researchers are bringing cardiovascular trials to the heart of the community
Cardiovascular disease (CVD), a broad term for conditions affecting the heart and blood vessels, remains the leading cause of death …
-
Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s
Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron replacement cell …
-
Can regulatory reform unearth LATAMs untapped potential for drug development?
Pivotal regulatory reform, digitalisation and improved regional cooperation are transforming countries such as Argentina, Brazil, Mexico, and other Latin America …
-
argenx to discontinue Phase III trials of thyroid eye disease therapy
argenx has announced the discontinuation of the Phase III UplighTED trials of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in …
-
Clinical Trials Arena Excellence Awards 2025: OSE Immunotherapeutics and One2Treat
OSE Immunotherapeutics, a biotechnology company that develops immunotherapies for cancer and autoimmune diseases, and One2Treat, a fast-growing technology company transforming …
-
Meet the new EmVenio at OCT events across 2026
Looking towards 2026, clinical trial teams continue to face challenges surrounding recruitment and retention, while many patients continue to confront …
-
Gilead’s HIV ART combo deemed non-inferior in second Phase III trial
Gilead Sciences’ human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven non-inferior to standard of care (SoC) in a …
